Democratic Congressman Says Trump Admin Signals Revolutionary Shift on Drug Policy Reform
Democratic Congressman Lou Correa believes the Trump administration presents an unprecedented opportunity to transform American drug policy.
Read More
Democratic Congressman Lou Correa believes the Trump administration presents an unprecedented opportunity to transform American drug policy.
Read More
A new study from Stanford University has uncovered unexpected results about ketamine’s role in treating depression.
Read More
This trial marks a significant departure and may reshape how clinicians combine traditional antidepressants and psychedelic therapy.
Read More
Texas has taken a bold step in mental health research by allocating $50 million to fund clinical trials of ibogaine.
Read More
What are ketamine practitioner's biggest pain points? Our 2025 Ketamine Practitioner Intelligence Research Report breaks it down.
Read More
Colorado Governor Jared Polis has signed a new bill allowing people with past psychedelic drug convictions to apply for pardons.
Read More
In a large study, cannabis and psychedelics emerged as the most highly rated treatments for treating eating disorders.
Read More
Johnson & Johnson's depression nasal spray Spravato continues its impressive growth trajectory, generating $414 million in Q2 2025 revenue.
Read More
These revenue leaks often remain invisible until they accumulate into thousands of lost income each month. Let's help you fix
Read More
The Australian government has announced that Spravato will be added to the Pharmaceutical Benefits Scheme starting July 1.
Read More